Toronto Patient in Sustained HIV Remission After Bone Marrow Transplant: What This Canadian First Means for Patients, Donors, and the Stem Cell Registry

What This Means for You

If you saw the weekend coverage of the Toronto patient in sustained HIV remission and your first reaction was either hope (for yourself, a partner, or a family member living with HIV) or curiosity about whether you should sign up for Canada's stem cell registry, this is the practical guide that the celebratory headlines did not include. The University Health Network announcement is a genuinely significant Canadian medical first, but the path from this single case to broader treatment access is narrow, slow, and hinges on practical decisions that ordinary Canadians can make this week — particularly around the stem cell donor registry, where Canada's pool of registered donors is materially smaller than other comparable countries.

Below is the action plan organized by who you are and what role you play in this story. The shortest version: stem cell donors aged 17-35 should sign up at blood.ca this week, especially if you are male, healthy, and from a non-European ancestry; people living with HIV in Canada should not stop antiretroviral therapy under any circumstances; and patients pursuing a stem cell transplant should ask their oncologist directly whether CCR5-delta 32 donor matching is feasible in their case.

If You Are Healthy and Aged 17-35: Join the Stem Cell Registry This Week

The single most concrete action any Canadian can take in response to this news is to register as a stem cell donor. According to Canadian Blood Services, you must be between the ages of 17 and 35, in good general health, and free of certain infectious diseases (including HIV/AIDS and hepatitis B and C) to register. Eligibility is the same regardless of whether you ultimately donate to a Canadian or international patient, since the global registry is interconnected.

Immediate action:

Go to blood.ca/en/stemcells/donating-stemcells/stemcell-eligibility-and-registration to confirm you meet eligibility criteria
Complete the online eligibility questionnaire at blood.ca/en/stemcells/donating-stemcells/stem-cells-questionnaire
Within 1-3 weeks you will receive a buccal (cheek) swab kit in the mail with a prepaid return envelope
Return the swab; HLA typing takes 4-6 weeks, after which you will be officially searchable on the global registry

What to prepare:

Approximately 15 minutes for the online questionnaire
A current address where Canada Post can deliver your swab kit
Realistic expectations: only about 1 in 430 registered donors are ever called to donate, and most who do donate via peripheral blood stem cell collection (a 4-6 hour outpatient procedure similar to platelet donation), not bone marrow surgery

Why male donors and donors from underrepresented ancestries matter most: According to Canadian Blood Services' published donor profile, transplant physicians overwhelmingly request male donors (lower complication rates, larger cell yield). Patients are also far more likely to find a match with a donor of similar ancestry. Canadian registrants are heavily skewed toward European-ancestry women, leaving Indigenous, Black, South Asian, East Asian, Middle Eastern, and Latin American patients with significantly lower match rates. If you are a healthy male in the eligible age range from any of these groups, your registration has disproportionately high expected value.

On the CCR5-delta 32 mutation specifically: Donors are not screened for the CCR5-delta 32 mutation at registration. If a transplant team needs to find a donor with this mutation for a patient who is both immunocompromised (requiring transplant) and HIV-positive, they conduct a separate, targeted search through the World Marrow Donor Association registries. The mutation is found in roughly 1% of people, almost exclusively those of northern European ancestry. Joining the standard registry means you may be available for either a standard HLA-matched search or, if you happen to carry the mutation, a CCR5-targeted search.

If You Are Living With HIV in Canada: What This Does (and Does Not) Mean

This is critical: the Toronto patient's case is not a treatment pathway available to people living with HIV who do not also have a serious blood cancer requiring stem cell transplant. According to UHN's announcement, the patient developed Stage 4 Burkitt's lymphoma in 1999 and acute myelogenous leukemia in 2021, with the bone marrow transplant performed because his cancer required it. The HIV remission was a remarkable byproduct of a high-risk procedure undertaken to save his life from cancer.

Practical takeaways:

Continue your antiretroviral therapy without interruption. Modern ART regimens (typically a single daily pill) suppress HIV to undetectable levels, and undetectable equals untransmittable (U=U). Discontinuing ART without medical supervision can cause viral rebound, treatment resistance, and serious health consequences within weeks.
Confirm coverage of your medications under your provincial drug plan. ART medications cost roughly $15,000-$25,000 per year at retail. They are covered in full or with co-pay through provincial HIV/AIDS drug programs (e.g., Ontario's Trillium Drug Program, BC's Centre for Excellence in HIV/AIDS, Quebec's RAMQ public drug plan, Alberta's Outpatient Cancer Drug Benefit Program adjacency, etc.) and the federal Non-Insured Health Benefits program for First Nations and Inuit.
Stay engaged with HIV research opportunities. Canadian sites participate in cure-focused trials including broadly neutralizing antibodies, bnAb infusions, latency-reversing agents, and gene therapies. The CIHR Canadian HIV Trials Network at hivnet.ubc.ca lists recruiting Canadian studies. Several do not require you to stop ART to participate.
Know that stem cell transplant is not a viable HIV cure path for the vast majority of people. Bone marrow transplant carries a 10-20% transplant-related mortality risk and lifelong immunosuppression complications. It is justifiable for a patient who needs the transplant for a life-threatening blood cancer; it is not an acceptable risk-benefit profile for HIV alone.

If You Are a Cancer Patient Considering Stem Cell Transplant and Are Also HIV-Positive

For the small number of Canadian patients in this specific situation — a serious blood cancer requiring allogeneic stem cell transplant, plus existing HIV — there are practical conversations to have with your transplant team.

Specific questions to ask your transplant physician:

Is CCR5-delta 32 donor matching feasible in my HLA profile? (The mutation is rare, and patients with non-European ancestry may have very few or zero CCR5-mutated matches available globally.)
If a CCR5-mutated donor is identified, does your centre have experience managing post-transplant HIV monitoring, including the gradual ART discontinuation timeline used in the Toronto case?
What are the specific transplant centres in Canada with experience in HIV-positive transplant recipients? (UHN Princess Margaret, Vancouver General, McGill University Health Centre, and several others have such experience; centre selection can affect outcomes.)
What is the expected timeline from HLA typing to transplant if a CCR5-targeted search is required? (International searches typically add 3-6 months versus a standard search.)

Insurance and financial planning:

Provincial health plans cover stem cell transplant procedures and inpatient care, but not all post-transplant medications or out-of-province travel for treatment
The Canadian Cancer Society Travel Treatment Fund (cancer.ca) provides limited financial assistance for patients traveling for treatment
Critical illness insurance, where held, often pays a lump sum on diagnosis of conditions including leukemia and lymphoma; review policies for definition specifics

For All Canadians: What You Can Do Even If You Are Not Eligible to Donate

Many Canadians want to support stem cell and HIV research after news like this but are outside the donor eligibility window. There are several practical pathways.

Practical steps:

Donate blood. Canadian Blood Services blood donations support patients undergoing transplant, who often require multiple blood and platelet transfusions during recovery. Eligibility window is broader (17 to no upper limit if otherwise healthy). Book at blood.ca/book.
Recruit eligible registrants in your network. Per Canadian Blood Services, peer recruitment is one of the most effective ways to add young, healthy male, ancestry-diverse donors to the registry. Forward the registration link to friends, family, and colleagues in the eligible age range.
Donate to HIV cure research. CANFAR (Canadian Foundation for AIDS Research) at canfar.com funds Canadian HIV cure research, including the immunology and virology research that supported the UHN team's monitoring of the Toronto patient.
Donate to UHN Foundation. Donations directed to the Princess Margaret Cancer Foundation (thepmcf.ca) or to UHN Foundation's HIV research programs support the clinical infrastructure that made this Canadian first possible.

The News: What Happened

According to a press release from University Health Network published on April 25, 2026, clinicians and researchers at UHN, Unity Health Toronto, and the University of Toronto have reported a Canadian first: a 62-year-old man living with HIV since 1999 is in sustained remission following a bone marrow transplant for cancer. As reported by Global News, the patient discontinued antiretroviral therapy in July 2025, and as of April 2026, HIV remains undetectable in his system using highly sensitive laboratory testing, with no HIV-specific immune responses detected.

According to the University of Toronto's Temerty Faculty of Medicine, the case was led by Dr. Sharon Walmsley, Director of the HIV Clinic at UHN's Toronto General Hospital, and Dr. Mario Ostrowski, clinician-scientist at St. Michael's Hospital (Unity Health Toronto), working with transplant and cancer specialists across the three institutions. The transplant was performed at the Hans Messner Allogeneic Transplant Program at UHN's Princess Margaret Cancer Centre and used donor stem cells carrying the CCR5-delta 32 mutation, identified through an international donor search.

According to UHN's announcement, the patient was originally diagnosed with Stage 4 Burkitt's lymphoma and HIV infection in 1999, then developed myelodysplastic syndrome as a long-term consequence of chemotherapy, which progressed to acute myelogenous leukemia in November 2021. The bone marrow transplant was undertaken to treat the leukemia. Approximately 1% of the population — primarily those of northern European descent — carries the CCR5-delta 32 mutation, which renders immune cells resistant to HIV by preventing the virus from entering through the CCR5 receptor.

According to CP24, only 10 patients worldwide are currently considered cured of HIV following similar procedures (commonly referred to as the Berlin patient, the London patient, the Düsseldorf patient, and others), and the Toronto patient would join this small group if he continues to have undetectable HIV levels for two and a half years after stopping ART — approximately the end of 2027.

Analysis: Why This Matters

Based on our analysis of this case alongside the international HIV cure literature and Canada's stem cell registry data, this development matters in three distinct ways that are worth separating to avoid common misinterpretations of breakthroughs of this kind.

First, it matters as a clinical proof point in Canada. Until now, the small number of HIV remission cases following CCR5-mutated donor transplants has been concentrated in European and U.S. centres. The UHN team's documented, peer-reviewable case adds a Canadian institution to the small group of centres globally with hands-on experience in this combined transplant-and-HIV remission protocol. For HIV-positive Canadian patients facing transplant in the future, this means a domestic centre with relevant expertise.

Second, it matters as a stem cell registry awareness moment. The Canadian Blood Services stem cell registry has a longstanding gap in donor diversity. Roughly 70% of Canadian registrants are female, while transplant teams overwhelmingly select male donors when possible. The registry is also disproportionately European-ancestry, leaving non-European patients with materially lower match rates. Each high-profile transplant story produces a measurable spike in registrations; the practical leverage point is converting that spike into registrations by underrepresented donor groups.

Third, it matters as a reminder of what stem cell transplant is not. Bone marrow transplant remains a high-risk procedure with substantial mortality and morbidity. The Toronto patient's HIV remission emerged from a transplant that was medically necessary for his leukemia. There is no responsible clinical pathway in which someone with HIV but without a transplant indication would undergo this procedure as a cure attempt.

Historical Context

The first reported case of HIV remission after a CCR5-mutated stem cell transplant was Timothy Ray Brown (the "Berlin patient"), reported in 2008-09. Adam Castillejo (the "London patient") was reported in 2019. Subsequent cases have been documented in Düsseldorf, New York, and Geneva, with each adding incremental knowledge about transplant conditioning regimens, timing of ART discontinuation, and post-transplant viral monitoring. Canadian and international researchers have generally characterized the procedure as proof-of-concept rather than scalable therapy.

What Happens Next

Based on the UHN team's published timeline, several developments are likely over the next 12-24 months. First, the Toronto patient's case will be submitted to peer-reviewed journals and presented at international conferences (likely the International AIDS Society Conference and the Conference on Retroviruses and Opportunistic Infections), adding methodological detail that will inform other transplant centres' protocols. Second, Canadian researchers — particularly the CIHR Canadian HIV Trials Network — will likely use the case to recruit for cure-focused studies that do not require transplant, including gene therapy approaches that aim to engineer CCR5 resistance into a patient's own cells. Third, Canadian Blood Services will likely publish updated registry recruitment messaging, and registration numbers should rise meaningfully in the weeks following the announcement.

Your Action Plan

Immediate (This Week):

If you are aged 17-35 and healthy, complete the stem cell registry eligibility questionnaire at blood.ca/en/stemcells/donating-stemcells/stem-cells-questionnaire
If you are living with HIV, confirm that your ART prescription is current and that any provincial drug plan coverage is in good standing
If you are a cancer patient who is also HIV-positive, ask your oncologist whether your case has been reviewed for possible CCR5-targeted donor matching
Forward this guide or the registry link to anyone in your network who is in the donor-eligible age range

Short-term (This Month):

If you registered, return your buccal swab kit promptly when it arrives (4-6 weeks of HLA typing follows return)
If you are HIV-positive, schedule your routine viral load and CD4 count checkup if you are due
Donate blood at blood.ca/book (eligibility is broader than stem cell registration)
Consider supporting CANFAR (canfar.com) or the Princess Margaret Cancer Foundation (thepmcf.ca)

Long-term (This Year):

If you are part of an underrepresented ancestry group, organize a registry drive in your community network or workplace
If you are a healthcare worker, follow updates from the CIHR Canadian HIV Trials Network for recruiting Canadian studies
Update your stem cell registry contact information annually so transplant teams can reach you if matched

Other Perspectives

UHN and Research Team View:

According to UHN's official announcement, the case is described as "a Canadian first" and as evidence of "sustained HIV remission and possible cure." Dr. Sharon Walmsley emphasized that the case offers hope while noting the high-risk nature of the procedure and that it is not a generalizable HIV treatment.

Canadian Blood Services View:

Per Canadian Blood Services' published registry guidance, peer recruitment of young, healthy male donors and donors from underrepresented ancestry groups remains the most acute registry need. Each high-profile transplant story typically produces a temporary spike in registrations.

HIV Community Organizations View:

Canadian HIV organizations including CATIE, the Canadian AIDS Society, and CANFAR have historically welcomed cure-related news while consistently emphasizing the importance of continued ART access, U=U messaging, and the distinction between research milestones and clinical treatment options for the broader HIV-positive population.

Cancer Patient Advocacy View:

The Leukemia and Lymphoma Society of Canada and similar organizations note that the Toronto patient's primary medical need was treatment of acute myelogenous leukemia, and that stem cell transplant outcomes for blood cancers continue to improve through both supportive care and targeted therapies that may, over time, reduce the need for high-conditioning transplant in some patient populations.

International Cure Research View:

The International AIDS Society and the Conference on Retroviruses and Opportunistic Infections research community generally characterize CCR5-targeted transplant cases as proof-of-concept rather than scalable therapy, and note that the parallel research program — engineering CCR5 resistance into a patient's own cells via gene therapy — is the more likely pathway to broader applicability.

Note: Including multiple perspectives doesn't imply all views are equally valid, but ensures readers can make informed judgments.

Corrections Policy

We strive for accuracy. If you find an error in this analysis, please email us at [email protected]. We will promptly investigate and correct any factual inaccuracies.

Updates:

No corrections to date (as of April 27, 2026)